FDA warns of risks of teething products with benzocaine
The US Food and Drug Administration has recently issued a statement ordering some manufacturers to halt production of teething products with benzocaine, warning the market of its dangers.
Although these may temporarily relieve a child’s teething pain, the agency said they may pose a “serious risk” to infants and children, according to a CNN report.
The risk includes having methemoglobinemia, a condition in which the oxygen level drops to a fatally low level. Symptoms include rapid heart rate, lightheadedness, difficulty breathing, sleepiness, headache, skin that is pale and nails that are blue or gray.
The symptoms can start as immediately as in a few minutes after a product is used. Babies who have been exposed to these products should get medical attention immediately.
“The FDA is taking steps to stop use of these products in young children and raise awareness of the risks associated with other uses of benzocaine oral health products,” FDA Commissioner Dr. Scott Gottlieb was quoted.
Benzocaine products are sold as gels, sprays, ointments, solutions and lozenges.
Brands that sell these products are Anbesol, Baby Orajel, Cepacol, Chloraseptic, Hurricaine, Orabase, Orajel and Topex and as store brands and generics.
Hyland’s homeopathic teething tablets recalled nationwide Church & Dwight Co., which sells and markets Orajel products for teething. The company also said it has discontinued the production of the products as the safety of its customers and their children is its highest priority.